Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Hematological Malignancies
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (2148
)
Lymphoma (1206
)
Leukemia (2148
)
Lymphoma (1206
)
›
Associations
(3919)
News
Trials
Search handles
@ADesaiMD
@AaronGerds
@AaronGoodman33
@Abdallah81MD
@AdrienContejean
@AkshaySharmaMD
@AlGarfall
@AlkaliDr
@Anand_88_Patel
@AnnaSureda5
@AshAlizadeh
@AshKishtagari
@AtrashShebli
@AuclairDan
@BenDiamondMD
@BijoyTelivala
@BiranNoa
@BldCancerDoc
@CLachowiez
@CanerSaygin
@CarmemBonfim1
@CathyEngMD
@CharuAggarwalMD
@ChelseaPinnix
@ChenyuLinMD
@CwynKate
@CyclingDoctor
@DanilovLab
@DavidSteensma
@Doc_Amarendra
@DoctorGRao
@DrAEvens
@DrChoueiri
@DrChrisPFox
@DrDanPersky
@DrEmmaHolliday
@DrEmmaSearle
@DrGarethMorgan1
@DrHKantarjian
@DrJFriedberg
@DrJulieVose
@DrLizBrem
@DrMCanales
@DrMDavids
@DrMMurphy
@DrMarcosdelima
@DrMiguelPerales
@DrNikitaMehra
@DrOlaLandgren
@DrPMPGI
@DrRakeshPopat
@DrRaulCordoba
@DrSGraff
@DrSapnaPatel
@DrYukselUrun
@Dr_AmerZeidan
@Dr_Daniel_Molin
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@Drjhoffmanmiami
@ESchattner
@EhsanMalekMD
@EileenMBoyle
@End_myeloma
@EshaKaul1
@FadiHaddad_MD
@Fer_martinmoro
@FrancescoMaura4
@GeorgeMikhaeel
@GlopesMd
@GomezDLeonMD
@GuiperiniMD
@HH_Oncodr
@HadidiSamer
@HayderSaeed_MD
@HemSandoval
@HenningWillers
@HenrychihangFu1
@HiraSMian
@HiraseMD
@ImanAboudalle
@JHillengass
@JanakiramMurali
@Jaskirat__SR
@JohnPLeonardMD
@JoshuaRichterMD
@JuanAlderuccio
@JulienMazieres
@LPopplew
@Latinamd
@LeonidasPlatan1
@LeukDocJZ
@LisaHicksMD
@Lymphoma_Doc
@MCWardMD
@MKD_BMT
@ManniMD1
@MediHumdani
@MeeraMohanMD
@Melanoma_doctor
@Mike_Oertel_MD
@MinnemaMonique
@Mohty_EBMT
@MorieGertz
@Myeloma_Doc
@MyriamChalabi
@NBahlis
@NagiSaghir
@NicoleKuderer
@NitinJainMD
@NoopurRajeMD
@OmarNadeemMD
@OncSadr
@Othman_Al_Sawaf
@PGrivasMDPhD
@PatrickHwuMD
@Prasshmehta
@ProfPadhani
@RManochakian
@RShouval
@RaajitRampal
@RabiHannaMD
@RahulBanerjeeMD
@RamonGarciaSanz
@RemyDulery
@RenoHemonc
@Rfonsi1
@RielyMD
@Rndubois
@RoloffGreg
@SCTNB
@SLentzsch
@SandyWong02111
@ShakiraG_MBBS
@ShannonWestin
@ShepardDale
@SimonLo21054188
@StefanoLuminari
@SuyogCancer
@SyedMAhmedMDPhD
@THilalMD
@TalhaBadarMD
@TaniaJain11
@TaylorJ_MD
@Transplant_Doc
@UroDocAsh
@UrviShahMD
@VPrasadMDMPH
@VanitaNoronha
@VincentRK
@VivekSubbiah
@VriesElisabeth
@aditishasMD
@adrianalegrea
@akeithstewart
@albertomussetti
@aljurf100
@andrew02114
@bdermanmd
@beatalleukemia
@binayshah
@bose_prithviraj
@calliecoombsmd
@cancerassassin1
@chadinabhan
@chanyooncheah
@connors_md
@davidhenrymd
@dawood_findakly
@dgermain21
@diegoah66
@docbraunstein
@doctorpemm
@drjgauthier
@drkomanduri
@drsangeetmd
@elizabeth_budde
@fabianaperna
@gloria_iacoboni
@graham74GC
@hematologo
@hemedoc
@hmgcoa2
@iHematologo
@i_yakoub_agha
@ixazebe
@j_marquet
@jaltmanmd
@jamecancerdoc
@jayastuMD
@jeff_sharman
@jrgralow
@jvalentingg
@kdjhaveri
@kporkka
@lane_andy
@lingarajnayak
@mahrefat
@majorajay
@manalipatelmd
@marklewismd
@matthew_mei
@mfrimawi
@michaelwangmd
@mike_dickinson1
@montypal
@mpdrc
@mshadman
@mtmdphd
@myelomatips
@n8pennell
@n_gangat
@ninashah33
@pb10_bmt
@pebarba
@pnbarry
@profghjackson
@rabonour1
@rajshekharucms
@rajuan_27
@ramsedhom
@rbryanbell
@rschilsky
@rubinstein_md
@samyamshon
@sejadiMD
@smbenlazar
@subatomicdoc
@syed_abutalibmd
@szusmani
@tanyawildes
@timfenske
@tmprowell
@tobyeyre82
@tomleblancMD
@weldeiry
@ymori117
Search handles
@ADesaiMD
@AaronGerds
@AaronGoodman33
@Abdallah81MD
@AdrienContejean
@AkshaySharmaMD
@AlGarfall
@AlkaliDr
@Anand_88_Patel
@AnnaSureda5
@AshAlizadeh
@AshKishtagari
@AtrashShebli
@AuclairDan
@BenDiamondMD
@BijoyTelivala
@BiranNoa
@BldCancerDoc
@CLachowiez
@CanerSaygin
@CarmemBonfim1
@CathyEngMD
@CharuAggarwalMD
@ChelseaPinnix
@ChenyuLinMD
@CwynKate
@CyclingDoctor
@DanilovLab
@DavidSteensma
@Doc_Amarendra
@DoctorGRao
@DrAEvens
@DrChoueiri
@DrChrisPFox
@DrDanPersky
@DrEmmaHolliday
@DrEmmaSearle
@DrGarethMorgan1
@DrHKantarjian
@DrJFriedberg
@DrJulieVose
@DrLizBrem
@DrMCanales
@DrMDavids
@DrMMurphy
@DrMarcosdelima
@DrMiguelPerales
@DrNikitaMehra
@DrOlaLandgren
@DrPMPGI
@DrRakeshPopat
@DrRaulCordoba
@DrSGraff
@DrSapnaPatel
@DrYukselUrun
@Dr_AmerZeidan
@Dr_Daniel_Molin
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@Drjhoffmanmiami
@ESchattner
@EhsanMalekMD
@EileenMBoyle
@End_myeloma
@EshaKaul1
@FadiHaddad_MD
@Fer_martinmoro
@FrancescoMaura4
@GeorgeMikhaeel
@GlopesMd
@GomezDLeonMD
@GuiperiniMD
@HH_Oncodr
@HadidiSamer
@HayderSaeed_MD
@HemSandoval
@HenningWillers
@HenrychihangFu1
@HiraSMian
@HiraseMD
@ImanAboudalle
@JHillengass
@JanakiramMurali
@Jaskirat__SR
@JohnPLeonardMD
@JoshuaRichterMD
@JuanAlderuccio
@JulienMazieres
@LPopplew
@Latinamd
@LeonidasPlatan1
@LeukDocJZ
@LisaHicksMD
@Lymphoma_Doc
@MCWardMD
@MKD_BMT
@ManniMD1
@MediHumdani
@MeeraMohanMD
@Melanoma_doctor
@Mike_Oertel_MD
@MinnemaMonique
@Mohty_EBMT
@MorieGertz
@Myeloma_Doc
@MyriamChalabi
@NBahlis
@NagiSaghir
@NicoleKuderer
@NitinJainMD
@NoopurRajeMD
@OmarNadeemMD
@OncSadr
@Othman_Al_Sawaf
@PGrivasMDPhD
@PatrickHwuMD
@Prasshmehta
@ProfPadhani
@RManochakian
@RShouval
@RaajitRampal
@RabiHannaMD
@RahulBanerjeeMD
@RamonGarciaSanz
@RemyDulery
@RenoHemonc
@Rfonsi1
@RielyMD
@Rndubois
@RoloffGreg
@SCTNB
@SLentzsch
@SandyWong02111
@ShakiraG_MBBS
@ShannonWestin
@ShepardDale
@SimonLo21054188
@StefanoLuminari
@SuyogCancer
@SyedMAhmedMDPhD
@THilalMD
@TalhaBadarMD
@TaniaJain11
@TaylorJ_MD
@Transplant_Doc
@UroDocAsh
@UrviShahMD
@VPrasadMDMPH
@VanitaNoronha
@VincentRK
@VivekSubbiah
@VriesElisabeth
@aditishasMD
@adrianalegrea
@akeithstewart
@albertomussetti
@aljurf100
@andrew02114
@bdermanmd
@beatalleukemia
@binayshah
@bose_prithviraj
@calliecoombsmd
@cancerassassin1
@chadinabhan
@chanyooncheah
@connors_md
@davidhenrymd
@dawood_findakly
@dgermain21
@diegoah66
@docbraunstein
@doctorpemm
@drjgauthier
@drkomanduri
@drsangeetmd
@elizabeth_budde
@fabianaperna
@gloria_iacoboni
@graham74GC
@hematologo
@hemedoc
@hmgcoa2
@iHematologo
@i_yakoub_agha
@ixazebe
@j_marquet
@jaltmanmd
@jamecancerdoc
@jayastuMD
@jeff_sharman
@jrgralow
@jvalentingg
@kdjhaveri
@kporkka
@lane_andy
@lingarajnayak
@mahrefat
@majorajay
@manalipatelmd
@marklewismd
@matthew_mei
@mfrimawi
@michaelwangmd
@mike_dickinson1
@montypal
@mpdrc
@mshadman
@mtmdphd
@myelomatips
@n8pennell
@n_gangat
@ninashah33
@pb10_bmt
@pebarba
@pnbarry
@profghjackson
@rabonour1
@rajshekharucms
@rajuan_27
@ramsedhom
@rbryanbell
@rschilsky
@rubinstein_md
@samyamshon
@sejadiMD
@smbenlazar
@subatomicdoc
@syed_abutalibmd
@szusmani
@tanyawildes
@timfenske
@tmprowell
@tobyeyre82
@tomleblancMD
@weldeiry
@ymori117
Filter by
Latest
8ms
And thanks to our many collaborators @WinshipAtEmory and elsewhere @ajaynookaMD @PariharCohen @nanostringtech @JKaufmanMD @EagleMyeloma @SagarLonialMD @MadhavDhodapka1 (@Hope34Me)
8 months ago
DAPK1 (Death Associated Protein Kinase 1)
8ms
SCI member @AshAlizadeh & others provide the first direct evidence for the presence of genetic alterations in circulating precursor cells years before overt #FollicularLymphoma development, dominated by CREBBP mutations within the KAT domain. https://t.co/dHkXrUJKIQ #lymsm (@SCIDirector)
8 months ago
CREBBP (CREB binding protein)
|
CREBBP mutation
8ms
@DrKrinaPatel is multi talented, now running a session on lymphoma CAR-T and presented some promising data on CD70 allo CAR-T in T cell lymphoma. This target may be used in #mmsm in future Hard disease and 2 pts cases with early promising results @DAVAOnc #DAVABermudaHeme (@HadidiSamer)
8 months ago
Clinical
|
CD70 (CD70 Molecule)
8ms
Excellent MDS session chaired by @beatalleukemia featuring @MikkaelSekeres @DrPinkalDesai & others - the topics included clinical trial endpoints, HMA-exposed AML, CCUS, and IRAK4 inhibitors! #mdssm #DAVABermudaHeme (@Anand_88_Patel)
8 months ago
Clinical
|
IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
8ms
Very cool to hear @beatalleukemia’s fascinating CCUS work at @DAVAOnc Bermuda: Based on compelling data that inflammation drives CCUS progression and that IL-1B blockade blocks it, they’ll be looking at this in an RCT with progression to MDS as endpoint. Exciting concept! https://t.co/uFZXu4mrqa (@RahulBanerjeeMD)
8 months ago
IL1B (Interleukin 1, beta)
8ms
At #DAVABermudaHeme @DrKrinaPatel discussing the challenges and therapeutic potential of IL-15 monotherapy in immuno-oncology. Including potential applications as a precursor or bridge to CAR-T therapy for #myeloma. (@drkomanduri)
8 months ago
Immuno-oncology
|
IL15 (Interleukin 15)
8ms
Always great to hear @LeukDocJZ discussing future of TP53 mutated myeloid disease #DAVABermudaHeme @DAVAOnc (@DrPinkalDesai)
8 months ago
TP53 (Tumor protein P53)
|
TP53 mutation
8ms
Great MDS/AML therapy session chaired by @MikkaelSekeres with @LeukDocJZ discussing the toughest population out there with TP53 mutated myeloid malignancies @DAVAOnc #BermudaHeme23 (@beatalleukemia)
8 months ago
Clinical
|
TP53 (Tumor protein P53)
|
TP53 mutation
8ms
Great @DAVAOnc Bermuda slide by @andrew02114 about cereblon modulation in #MMsm, grouped not by drug but by specific targets. Nice segway to @adamssperling’s work about TP53 mutations emerging with len but not with pom. Hopefully some day SPMs will be a thing of the past! (@RahulBanerjeeMD)
8 months ago
TP53 (Tumor protein P53) • CRBN (Cereblon)
|
TP53 mutation
8ms
“With t(4;14), there’s FGFR3, MMSET, IgH, and NSD2. Everything just seems like random letters and numbers strung together.” 🤣 Very much agree - thank goodness #MMsm docs like @andrew02114 are trying to figure out how to target t(4;14) beyond just bortezomib! (@DAVAOnc Bermuda) (@RahulBanerjeeMD)
8 months ago
FGFR3 (Fibroblast growth factor receptor 3) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
|
bortezomib
8ms
Check out our interview with @wwierda of @MDAndersonNews, who outlines disease characteristics impacting treatment decisions in CLL, including the role of TP53, del(17p), and IgHV mutations: 👉 https://t.co/D50LqhCHtd 👈 @EHA_Hematology #EHA2023 #LeuSM #CLLsm #HemOnc (@VJHemOnc)
8 months ago
Interview
|
TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
|
IGH mutation
8ms
Patients with myeloma, learn from @bdermanmd as he discusses MRD in multiple myeloma in patient-friendly language. https://t.co/iQOXGZrO8v #mmsm clonoSEQ is FDA-cleared to assess MRD in MM, CLL and B-ALL. For further info & test limitations: https://t.co/sE39cuZxFD (@clonoSEQ)
8 months ago
Clinical
|
clonoSEQ
8ms
#ICYMI the July issue— A Phase Ib/II Study of Ivosidenib with #Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies, by @CLachowiez et al. https://t.co/PDtssjLQyN @OHSUSOM #leuSM (@BCD_AACR)
8 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)
8ms
👀 nothing 2000 mg/m2 Cy can’t fix! Including Parkinsonism after cilta-cel #MMsm following workup. Fascinating that 95% of T-cells after slug of Cy still CAR+, but still worked rapidly! Well-written @BloodJournal case by @MJFzeta @MarcelaMaus @OncSadr @andrew02114 et al! (@RahulBanerjeeMD)
8 months ago
SNAI2 (Snail Family Transcriptional Repressor 2)
|
Carvykti (ciltacabtagene autoleucel)
8ms
He did so much, not only for myeloma, but also for hematology in Spain. I hope that his fellows maintain his vision. #GraciasDrSanMiguel, @BrunoPaiva_UNAV @mvmateos #myeloma #msmm (@CaersJo)
8 months ago
8ms
Learn about new #BTKinhibitor options, antibodies, BCL2 inhibitors, & cellular therapy for #CLL treatment from @DrMDavids @AdamKittai @wwierda & Dr. Lamanna! This activity from #ASCO23 provides clear guidance & strategies for optimal treatment: https://t.co/YuFAL21ldw @PeerView (@CllSociety)
8 months ago
8ms
Congratulations to @EAonc Myeloma Committee Chair @VincentRK, on this prestigious appointment @IMFmyeloma (@eaonc)
8 months ago
8ms
Link to article https://t.co/O1h3yhjm5H and thanks to @BloodCancerJnl @VincentRK @Rfonsi1 for supporting this work! (@HiraSMian)
8 months ago
8ms
Congratulations 👏 @VincentRK 👏 on your appointment as Chairperson-Elect of the International Myeloma Foundation (@IMFmyeloma.) I look forward to working with you and continuing to bring hope to #myeloma patients. #mmsm (@NorthTxMSG)
8 months ago
Clinical
8ms
Check out our new Review: Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice https://t.co/ot1gyAtkLp #mpnsm @britsochaem @draevens @wileyonc_hem #myelofibrosis (@e_JHaem)
8 months ago
Clinical • Review
8ms
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd (@mtmdphd)
8 months ago
8ms
My brother has leukemia, and I want to ask for help (@lwbwant)
8 months ago
8ms
🗣️:🇺🇲/👥: 👨⚕️🩸🦀 🤔 Peripheral flow cytometry for a possibility of firstly hairy cell leukemia and than marginal zone lymphoma. Bone marrow Asp&biopsy for BRAF mutation, and further differantiate possible causes. If one of them watch & wait might be a rational solution. (@Dr_MSU)
8 months ago
Biopsy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
8ms
👉Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia by Thomas Kipps @JCO_ASCO https://t.co/np2QeXw3Az (@SLentzsch)
8 months ago
Clinical • Minimal residual disease
8ms
Francesca Castro @fcastroRD and I discuss practical nutrition tips as well as common questions and myths around healthy dietary patterns @MSK_DeptOfMed @MSKCancerCenter @HealthtreeMM @IMFmyeloma @ASH_hematology https://t.co/w2d2qsQZta #mmsm #cancer #nutrition (@UrviShahMD)
8 months ago
Clinical
8ms
👉👉👉Congratulations to our superstar #PharmD Dr @CRausch_PharmD for being awarded #40Under40inCancer & to all awarded!! Also welcome @CRausch_PharmD to @Twitter as our newest friend & colleague to join #medtwitter !! #leusm #MPNSM #BPDCN | @Marxk @YLeyfman @ajperissinotti (@doctorpemm)
8 months ago
8ms
New manuscript published in @BloodAdvances validating the new "Severe4" comorbidity index to predict post-CAR-T outcomes in DLBCL, with our @CULymphoma faculty Drs. @StevenBairMD and @mana1981 contributing. #lymsm #celltherapy cc @DanilovLab https://t.co/yi58TtfUz5 (@CULymphoma)
8 months ago
8ms
Please sign up for this meeting in #radiotherapy for #lymphoma patients, #lymphsm @WomenInLymphoma @Dr_Daniel_Molin @LenaSpecht1 @glimelius (@glimelius)
8 months ago
Clinical
8ms
Introducing @MeeraMohanMD (@MedicalCollege): speaker at our 2023 Wisconsin Multiple Myeloma & Lymphoma Summit! We're excited for this session, make sure to attend August 26 in Milwaukee. ➡️LEARN MORE: https://t.co/EbFkMP5Kr8 #CME #Oncology #MultipleMyeloma #Lymphoma (@btfoundation)
8 months ago
CME
8ms
Just out @BloodAdvances 🚨 Our systematic review & meta-analysis of infections following bispecific antibodies in myeloma led by @GemmaKReynolds We look at infections in 1666 BsAb trial patients, including #ASH22 data 🧵👇 https://t.co/v9GBiGLybo #mmsm #EHA23 @ManniMD1 1/x (@Eddie_Cliff)
8 months ago
Retrospective data • Review
8ms
I hope MGUS screening in osteoporosis clinics can now stop (@ollielomas)
8 months ago
8ms
ICYMI: What's the current state of CAR-T access for MM? In this video from the myeloma roundtable series, @szusmani of @MSKCancerCenter; @YiLinMDPhD of @MayoClinic; Shambavi Richard, MD of @TischCancer; and @MeeraMohanMD of @MedicalCollege, weigh in. 📺: https://t.co/avUlp8bgVe (@Blood_Cancers)
8 months ago
Video
8ms
Our @NatureComms paper is published👉checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease👉new role of PD-1H in bone biology independent of its known immunoregulatory functions #mmsm @BMT_updates @columbiacancer https://t.co/HPEu4gmmuz (@SLentzsch)
8 months ago
Checkpoint inhibition
|
VSIR (V-Set Immunoregulatory Receptor)
8ms
Living with a #multiplemyeloma often requires patients to take up to four medications, as tolerated. In @healthcentral, our specialist @docbraunstein of @NYULISOM_HemOnc shares tips and resources from @theMMRF for patients managing combination therapy: https://t.co/RdXVYigsc7 (@Perlmutter_CC)
8 months ago
Clinical • Combination therapy
8ms
Agree, very interesting and much needed. Perhaps adding a hypomethylating agent to high risk myeloma treatment warrants reexamination since the demise of panabinostat. (@CamilleAbboud10)
8 months ago
8ms
Ph3 RCT Len vs Obs in SMM [10/25/19] @SagarLonialMD @SJ_OncBiostats @Rfonsi1 @mweissthedacare @myelomaMD @Myeloma_Doc @kaufman_MMdoc @AYACOUB7 Buadi, O’Brien @MileHighMyeloma Anderson et al. @VincentRK @JCO_ASCO https://t.co/J5KR4xhcPT #mmsm #EAonc E3A06 @eaonc #NCT01169337 (@mtmdphd)
8 months ago
8ms
Are you current on modern therapeutics for patients with #AML? Watch Drs. @Daver_Leukemia, @beatalleukemia, Harry Erba, & Amir Fathi discuss the latest in this CME video, taken from our recent event at #ASCO23. Produced in partnership with @HealthTreeAML. https://t.co/XX5nNy0fKz (@PeerView)
8 months ago
Clinical • Licensing / partnership • CME • Video
8ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
8 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
8ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
8 months ago
lenalidomide • Darzalex (daratumumab)
8ms
It is for my 2 friends who have been diagnosed with cancer this year, and have died very quickly from it. One blood cancer (unclear which it was so fast) and one breast. You don’t go from symptomless to dead with breast cancer in your early 50s within 4 months usually. (@mumzles1)
8 months ago
8ms
Dr. @aditishasMD at @MDAndersonNews Leukemia giving an excellent talk on the role of STAT3 in AML! it is not everyday that a speaker shows you a pic of their own mitochondria 😲… that’s next level dedication. Sadly I wasn’t fast enough to take a pic of her mitochondria #leusm (@sanamloghavi)
8 months ago
STAT3 (Signal Transducer And Activator Of Transcription 3)
8ms
Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML - @DrHKantarjian #cancer #leukemia #MDAndersoncancercenter #researchers #venetoclax #aml #oncology #drugs #oncodaily https://t.co/xblGnHD2vX (@oncodaily)
8 months ago
Clinical
|
Venclexta (venetoclax)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login